ELIZABETH DOUVILLE

Elizabeth Douville stands as a prominent figure in the Canadian life sciences investment landscape, serving as the Managing Partner at Amorchem. Her leadership is central to Amorchem's mission of identifying, funding, and developing groundbreaking early-stage drug discovery and therapeutic companies. With a career spanning decades in both scientific research and venture capital, Ms. Douville brings a unique blend of deep scientific understanding and astute investment acumen to her role.

At Amorchem, Elizabeth Douville is responsible for overseeing investment strategies, leading due diligence processes, and actively supporting portfolio companies. Her investment focus is primarily on early-stage opportunities within the life sciences sector, including novel therapeutics, biotechnology, and pharmaceutical innovations. Amorchem's strategy under her guidance involves providing crucial seed and Series A funding, coupled with hands-on operational and strategic support, to help promising scientific discoveries translate into viable commercial products. The firm often targets companies emerging from academic research institutions, particularly in Quebec and across Canada, aiming to bridge the gap between scientific innovation and market readiness.

Ms. Douville's extensive career background is a testament to her profound expertise. She holds a Ph.D. in Biochemistry from Université de Montréal, laying a strong scientific foundation. Prior to co-founding Amorchem, she held significant positions that shaped her understanding of both the scientific and business sides of biotech. Notably, she served as Scientific Director at BioChem Pharma, a pivotal Canadian biotech company, where she gained invaluable experience in drug development and research management. Her transition into venture capital saw her contribute to BioCapital, another key player in the Canadian investment scene, before she channeled her vision into establishing Amorchem. This journey equipped her with a comprehensive perspective on the challenges and opportunities inherent in early-stage life science ventures.

Under Elizabeth Douville's leadership, Amorchem has built an impressive portfolio and achieved notable successes. While specific individual investments she has personally led are often part of a collective firm effort, her strategic direction has been instrumental in the growth and successful exits of several portfolio companies. A prime example is Inversago Pharma, a company focused on metabolic disorders, which was successfully acquired by Novo Nordisk, demonstrating Amorchem's ability to identify and nurture high-potential ventures. Other companies like NuChem Therapeutics and ExCellThera also reflect the firm's commitment to advancing innovative science. Her work at Amorchem continues to significantly contribute to the vitality and growth of the Canadian biotech ecosystem, fostering the development of new treatments and therapies that address unmet medical needs globally.